Table-II.
Baseline characteristics.
| Characteristic | Study population (n = 69) |
|---|---|
| Demographic data | |
| Age, years | 42 (18–77) |
| Gender, female | 26 (37.7) |
| Primary disease | |
| Myocarditis | 40 (58.0%) |
| Coronary heart disease | 13 (18.8%) |
| Pneumonia (viral/interstitial/aspergillus) | 6 (8.7%)/1 (1.4%)/1 (1.4%) |
| Pulmonary contusion | 3 (4.3%) |
| Pulmonary arterial hypertension | 2 (2.9%) |
| Lung cancer with airway obstruction | 1 (1.4%) |
| Aortic dissection | 1 (1.4%) |
| Allergic shock | 1 (1.4%) |
| MRSA prophylactic regimens | 23 (33.3%) |
| Laboratory findings (Pre-ECMO) | |
| White blood cell, 103/mm3 | 11.5 (2.2–37.7) |
| Hemoglobin, g/dL | 120.0 (61–176) |
| Platelets, 103/mm3 | 174 (11–857) |
| CRP, mg/dL | 32 (1–194) |
| Lactate, mM | 3.8 (1.0–20.0) |
| Total bilirubin, mg/dL | 14.6 (4.3–131) |
| Creatinine, mg/dL | 98.5 (44–466) |
| Pre-ECMO SOFA score | 8 (0–22) |
| Pre-ECMO ventilator support, days | 0 (0–9) |
| Pre-ECMO ICU stay, days | 0 (0–4) |
| Pre-ECMO hospital stay, days | 0 (0–14) |
| Veno-arterial mode | 58 (84.1%) |
| Ventilator duration before ECMO weaning, days | 7 (0–32) |
| ECMO support duration, h | 154 (55–727) |